Zain Majid*

Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, SIUT, Karachi, Pakistan

*Corresponding Author: Zain Majid, Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, SIUT, Karachi, Pakistan.

Received: December 26, 2023; Published: January 01, 2024

Abstract

Ulcerative colitis (UC) is a chronic disease of the large bowel that affects all age groups [1].

References

1. D'Amico F., et al. “Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therapeutic Advances in Gastroenterology 12 (2019): 1756284819848631.
2. Padda IS., et al. “Tofacitinib”. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing (2023).
3. Palasik BN and Wang H. “Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis”. Journal of Pharmacy Practice 6 (2021): 913-921.
4. Magro F and Estevinho MM. “Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterology Journal 7 (2020):755-763.

Citation

Citation: Zain Majid. “Tofacitinib- the Turning Point in the Management of Ulcerative Colitis".Acta Scientific Gastrointestinal Disorders 7.2 (2024): 01.

Copyright

Copyright: © 2024 Zain Majid. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.